Provided are anti-infection effects of a heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) and use thereof. In particular, provided are use of hnRNPA2B1, a nucleic acid molecule encoding the protein, and an accelerator thereof or an inhibitor thereof in the preparation of a product for preventing and/or treating infectious diseases and/or diseases and/or conditions associated with infection, and a corresponding pharmaceutical composition or kit thereof. The present disclosure can be used for preventing and inhibiting infections (such as virus infections) and diagnosing and treating autoimmune diseases related to self-nucleic acids, and has wide application prospects.

The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks.

Disclosed herein are methods and compositions related to single chain antibody fragments which specifically bind nucleolin (NCL). Also disclosed are treating and diagnosing diseases using single chain antibody fragments that bind nucleolin.

This invention relates to kits including novel oral food challenge meal formulations. In particular, the invention also relates to kits including novel oral food challenge meal formulations, wherein the placebo dose formulation is indistinguishable from non-placebo dose formulations.

The disclosure relates to a diagnosis method and diagnosis device of ecotoxicity of solid waste soil in a pesticide production site. The diagnosis method is as follows: performing multi-point distributed collection on solid waste soil of a to-be-diagnosed pesticide production site, and subsequently pretreating the connected soil sample; synchronously performing a first toxicity test, a second toxicity test and a third toxicity test on the pretreated solid waste soil by using the diagnosis device. The diagnosis device comprises a first test device, a second test device and a third test device. The method of the disclosure is used for synchronous diagnosis of ecotoxicity by utilizing multiple diagnosis methods, and therefore is high in diagnosis efficiency and high in accuracy rate.

The disclosure relates to a diagnosis method and diagnosis device of ecotoxicity of solid waste soil in a pesticide production site. The diagnosis method is as follows: performing multi-point distributed collection on solid waste soil of a to-be-diagnosed pesticide production site, and subsequently pretreating the connected soil sample; synchronously performing a first toxicity test, a second toxicity test and a third toxicity test on the pretreated solid waste soil by using the diagnosis device. The diagnosis device comprises a first test device, a second test device and a third test device. The method of the disclosure is used for synchronous diagnosis of ecotoxicity by utilizing multiple diagnosis methods, and therefore is high in diagnosis efficiency and high in accuracy rate.

A method for early stage pathology detection, location, imaging, evaluation, and treatment of cells and/or extracellular vesicles in the circulation.

Disclosed herein are methods and non-human mammals for in vivo functional genomic screens.

The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.

The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin β1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.